Background {#Sec1}
==========

Delirium is defined as acute brain dysfunction characterized by an inability to focus, sustain, or shift attention that develops quickly and tends to fluctuate throughout the day \[[@CR1]\]. Nearly 70% of older adults who become critically ill and require hospitalization in the intensive care unit (ICU) develop delirium. ICU delirium can lead to immediate in-hospital complications including a longer length of ICU and hospital stay, increased risk of in-patient mortality, and elevated costs of care. In addition, ICU delirium is associated with long-term post-discharge complications, such as the development of cognitive impairment and dementia \[[@CR2]--[@CR5]\].

Delirium can be considered a cytokine-mediated inflammatory syndrome. The cytokine-mediated systemic inflammation eventually results in microglial and astrocyte activation, neuroinflammation, and lower levels of neuroprotection \[[@CR6]--[@CR8]\]. The combination of these three factors can increase the risk of delirium. These biochemical changes associated with delirium can then persist, albeit at a lower level, and may result in a chronic state of neuroinflammation, neurotoxicity, diminished neuroplasticity, and cholinergic failure, which then eventually manifests as long-term ICU-acquired cognitive impairment, dementia, or Alzheimer disease (AD, see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Proposed pathophysiologic model linking delirium and dementia (*number of arrows* depicting magnitude)

Physical activity has been found to enhance angiogenesis, neurogenesis, the release of neurotrophic factors, and neuroplasticity in animal studies \[[@CR9]--[@CR11]\]. Exercise has also been found to increase cerebral blood flow, oxygen extraction and glucose use, and reduce inflammation \[[@CR12], [@CR13]\]. Older patients who perform aerobic exercise showed the greatest increase in blood volume in frontal and parietal lobe white matter \[[@CR14]--[@CR18]\]. Executive cognitive ability showed the largest response to exercise as compared to other cognitive domains. Gains were also greater for training that lasted 30--45 min (versus longer or shorter) and older subjects (versus ones that were age 55--65) \[[@CR19]--[@CR25]\]. Physical activity also improves cognition in well older adults, and those with mild cognitive impairment, AD, stroke, chronic obstructive pulmonary disease (COPD), and traumatic brain injury \[[@CR19]--[@CR25]\].

Cognitive training has also been demonstrated to have favorable cognitive effects. The largest and most rigorous investigation of the efficacy of cognitive training is the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) trial. ACTIVE randomized 2802 well-functioning, community-dwelling adults (65 years and older) to Memory, Reasoning, Speed of Processing training, or a no-contact control group \[[@CR26]\]. Each ACTIVE intervention produced an immediate improvement in the trained ability with largest improvements observed for the Speed of Processing intervention followed by Reasoning and Memory. Treatment effects were maintained for 5 years on Memory, Reasoning, and Speed trained participants relative to controls and up to 10 years for Reasoning and Speed. A recent meta-analysis of trials of cognitive training on persons with MCI also found mild to moderate cognitive benefits from cognitive training although the long-term effects are not clear \[[@CR27]\].

The biochemical pathways through which physical and cognitive exercise can improve cognition are still being characterized. Physical exercise appears to mitigate endothelial dysfunction and vascular wall inflammation, and enhances neural substrates brain-derived neurotrophic factor (BDNF) and insulin growth factor-1 (IGF-1) that maximize the effects of subsequent cognitive stimulation \[[@CR28], [@CR29]\]. Similarly, cognitive therapy may exert its favorable effect by increasing levels of BDNF. This was shown in a randomized trial of 8 weeks of cognitive therapy versus health education among patients with heart failure \[[@CR30]\]. Patients randomized into the cognitive therapy arm showed an increase in their BDNF levels at 8 weeks compared to baseline levels as well as improvement in working memory, whereas the BDNF levels decreased in the education control.

Based on the prior work and the pathophysiologic mechanisms described above, the Improving Recovery and Outcomes Every Day after the ICU (IMPROVE) clinical trial was developed to test a novel home-based combined physical exercise and cognitive training program for older ICU survivors with delirium to improve cognitive impairment. Figure [2](#Fig2){ref-type="fig"} describes the conceptual model behind the study. In this model, physical exercise has an inducing effect on neural proliferation while cognitive training promotes the long-term functional integration of these new neural elements into adaptive networks \[[@CR9], [@CR10]\]. Thus, the enhancement in neural function and cognitive capacity produced by the combined intervention is hypothesized to result in improvement in ICU-acquired cognitive disability, and ultimately a delay in the time-to-onset of Alzheimer disease and related dementias. Improvements in physical and behavioral performance will be reflected as improved insulin resistance, VO2 max, muscle mass, and cognitive ability and mood. These cascades of physiological and behavioral changes result in very broad levels of improved cognitive performance, mood symptoms, functional independence, and quality of life.Fig. 2Conceptual model of the IMPROVE study

Based on the above findings, we hypothesize that combined physical exercise and cognitive training will produce improved biologic and physiologic substrates with increased BDNF and IGF-1 leading to neural proliferation and improved inflammatory environment \[decrease in tumor necrosis factor (TNF)-α, interleukin (IL)-1, 6, 8, and C-reactive protein (CRP)\]. These changes in turn will promote improvements to brain structure (increased frontal and temporal gray matter density) and neural activation, and reduce astrocyte and microglial activation \[decrease in S-100β and glial fibrillary acidic protein (GFAP)\].

The primary outcome of IMPROVE is to determine the effects of the combined physical exercise and cognitive training on the cognitive function of ICU survivors aged 50 and older*.* The secondary outcomes of IMPROVE are to determine the effects of the combined physical exercise and cognitive training on physical performance, anxiety and depressive symptoms, and quality of life of this patient population, and to examine the mechanisms of action of combined training by measuring biomarkers relevant to delirium and dementia \[[@CR6], [@CR31], [@CR32]\].

Methods/Design {#Sec2}
==============

Study setting and design {#Sec3}
------------------------

This protocol is described as required by the 2013 SPIRIT guidelines to ensure consistent reporting of clinical trials (see Additional file [1](#MOESM1){ref-type="media"}). Study design is depicted in Fig. [3](#Fig3){ref-type="fig"}. Subjects will be randomized to one of four arms: cognitive control and physical exercise control; cognitive control and physical exercise; cognitive training and physical exercise control; and cognitive training and physical exercise. A total of 344 subjects will be enrolled. 86 subjects will be randomized to each arm.Fig. 3Eligibility, randomization, allocation, and follow-up outcomes

The target population for the IMPROVE trial is adults aged 50 and older who have survived a critical illness in the ICU and had a delirium episode during their ICU stay at any of the three Indiana University School of Medicine-affiliated hospitals; IU Health (IUH) Methodist Hospital; IUH University Hospital; and Eskenazi Hospital. Trained research assistants will screen eligible individuals (those who meet inclusion criteria and do not meet any exclusion criteria) who will be screened twice per day for delirium until ICU discharge using the Confusion Assessment Method for the ICU (CAM-ICU) \[[@CR33]\]. Patients who screened positive on the CAM-ICU and survived the ICU stay will be approached for enrollment into the study within 48 h of their anticipated hospital discharge.

Study staff will complete a baseline assessment consisting of measures of cognition, physical function, depression and anxiety, and quality of life within 2 weeks of hospital discharge (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). Blood samples will also be collected from the participants at the time of baseline assessment. After the initial assessment, study subjects will be randomized to study groups. Randomization will be stratified by age (50-64, 65--75, older than 75), and by hospital site (Eskenazi, University, Methodist), for a total of 9 strata. A computer-generated randomization within stratum will be done using random blocks of 8 or 12, stratifying by discharged home versus discharged other (80% randomization block size 4 : 20% randomization block size 8). The risk of patient withdrawal will be addressed through the following approaches: availability of make-up sessions, availability of individual training sessions, study staff follow-up with the study participant if participation is less than 80%, and gift certificate incentives for completion of 3 and 6 months follow-up assessments.Fig. 4Schedule of enrollment, interventions, and assessments. GAD-7 Generalized Anxiety Disorder-7; PHQ-9 Patient Health Questionnaire-9; RBANS Repeatable Assessment of Neuropsychological Status; SF-36 36-Item Short Form Health Survey; SPPB Short Physical Performance Battery

Outcomes assessments will be conducted by research assistants who are blinded to randomization assignment at 3 and 6 months post baseline. Outcomes assessments consist of measures of cognition, physical function, depression and anxiety, and quality of life (see Outcome measures section in Fig. [4](#Fig4){ref-type="fig"}). Data will be collected and stored using Research Electronic Data Capture (REDCap). Research assistants will undergo training and certification procedures with a supervisor for quality assurance. Ongoing quality assurance checks are performed by the supervisor at regular intervals. Subjects will be instructed not to discuss their assigned intervention with the research assistants.

Participants {#Sec4}
------------

Participants must meet all the inclusion criteria below:Age ≥ 50 yearsAdmitted to medical or surgical ICU at Methodist, University, or Eskenazi hospitalsEnglish-speakingDischarged home or subacute rehabilitationAble to provide consent or has a legally authorized representative to provide consentAccess to a telephoneHave at least one episode of delirium as determined by the Confusion Assessment Method in the ICU

Participants who meet any of the following criteria will be excluded:Diagnosis of cancer with short life expectancyCurrent chemotherapy or radiation therapyHistory of dementing illnesses and other neurodegenerative diseases such as Alzheimer disease, Parkinson disease, or vascular dementiaCurrent alcohol consumption ≥ 5 drinks per dayVision \< 20/80 via Snellen cardLow hearing or communicative ability (examiner rated) that would interfere with interventions and outcome assessmentsPresence of delirium at time of hospital dischargePresence of American College of Sports Medicine absolute or relative contraindications to exerciseRecovering from a skeletal fractureStroke as the admitting diagnosis or a new event during the course of hospitalizationRecent history of drug abuse \[Drug Abuse Screening Test (DAST-20) score \> 5\]

Interventions {#Sec5}
-------------

Enrolled subjects randomized to the active cognitive intervention will receive facilitator-led cognitive training via computer-accessed online training modules 45 min per session, 2 days per week for 3 months; and physical exercise delivered by trained facilitators to participants in their homes via Internet-based single or multi-party (2--6 per group) videoconference 45 min per session, three times per week for 3 months.

The active cognitive intervention consists of several modules from Brain HQ developed by Posit Science, Inc., that engage time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, dual task, and memory. Exercises adapt to participants' level of performance and automatically advance in difficulty level as performance improves.

The cognitive control intervention consists of control modules also from Brain HQ. The cognitive control activities happen at the same frequency as the active cognitive intervention.

The active physical exercise intervention consists of 45 min of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. Three sessions per week for 3 months will be delivered. Participant's heart rate and rating of perceived exertion (RPE) will be used to ascertain achievement of moderate intensity exercise. Participants will be advised to exercise at the RPE level of 5--6 on a 10-point scale, equating to moderate-intensity exercise for adults over the age of 40 years. Each physical exercise session will be divided as follows: 5 min of warm-up, 10 min of upper-body, 10 min of core, 10 min lower-body, 5 min of upper-body and lower-body, and 5 min of cool-down and flexibility exercises. All exercises will be conducted from a seated position in a solid backed chair.

The physical exercise control will consist of gentle, seated stretching. Three sessions per week for 3 months will be delivered.

Outcome measures {#Sec6}
----------------

The primary outcome will be cognitive performance at 3 and 6 months. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total index score will provide the primary outcome for the trial \[[@CR34]\]. Secondary outcomes will be assessed using individual tests of processing speed, executive control, and new learning ability as follows: Trail Making Test Part A and B (seconds to complete), and Stroop Color and Word Test (interference trial). These measures sample major domains of cognition affected in ICU survivors.

Secondary outcomes will also include mood symptoms, physical performance, quality of life, and biomarkers relevant to delirium and dementia. All secondary outcomes, except for biomarkers, will be measured at 3 and 6 months. Mood symptoms will be assessed with Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Scale-7 (GAD-7) to determine the impact of the intervention on the ICU's survivors' mood and anxiety. The PHQ-9 is a nine-item depression scale with a total score from 0 to 27 \[[@CR35], [@CR36]\] and the GAD-7 is a seven-item anxiety scale with a total score from 0 to 21 \[[@CR37], [@CR38]\].

Physical training effects on balance and strength will be assessed via the Short Physical Performance Battery (SPPB), a validated objective assessment \[[@CR39], [@CR40]\]. The SPPB yields a performance score of 0--12 (0--4 poor, 5--7 intermediate, 8--12 good). A difference of 1 point indicates a significant change in function. Physical training effects on cardiovascular fitness will be assessed via the 2-min step test and grip strength. The 2-min step test for cardiovascular fitness is a validated measure of aerobic capacity, does not require equipment, and can be used in the home setting. Grip strength will be measured using a JAMAR hand dynamometer \[[@CR41]\].

The Medical Outcome Study Short Form (SF-36) will be used to measure quality of life. It has eight components (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) that are aggregated into a Physical Component Summary (PCS) and a Mental Component Summary (MCS). The PCS and the MCS will be used as quality of life outcomes.

Biomarkers will be measured at baseline and 3 months: pro-inflammatory cytokines (IL-1, 6, 8, TNF-α); the acute-phase reactant (CRP); neurotrophic factors \[IGF-1, vascular endothelial growth factor (VEGF), BDNF\]; markers of glial dysfunction and astrocyte activation (S-100β, GFAP); and AD-related biomarkers (*APOE* genotype, plasma amyloid-β Aβ42/Aβ40) \[[@CR31], [@CR32]\].

Statistical analyses {#Sec7}
--------------------

Statistical analyses will be conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). Differences in patients' baseline characteristics among the four groups will be compared using analysis of covariance (ANCOVA) for continuous variables and the Cochran-Mantel-Hansel statistic for categorical variables while adjusting for stratification variables.

Mixed effects models will be used with repeated RBANS scores collected at baseline, 3 months, and 6 months as the outcome measures, group, time, and a group by time interaction as independent variables while adjusting for stratification variables and other potential baseline covariates found to be significantly different in univariate comparisons. A significant interaction between group and time would indicate differences in changes of cognitive functions over time among the four groups. Post hoc comparisons will be conducted following a significant interaction between group and time to compare the effect of the combined training group to the other three groups (attention control, cognitive training only, and exercise only groups) at 3 month for immediate training effect and at 6 months for sustained training effect. Separate mixed-effect models will also be used for repeated Trail Making Test Part A and B and Stroop Color and Word Test.

Similarly, separate mixed-effects models will be used with repeated measures (SPPB, 2-min step, PHQ-9, GAD-7, SF-36 PCS and MCS) as the outcome variables, group, time, and interactions between group and time as independent variables, while adjusting for stratification variables and other baseline covariates that may be different among the four groups. Significant interactions between group and time in these models would indicate differences in changes of functional outcomes, depressive symptoms, and anxiety levels or quality of life over time among the four groups. Post hoc analyses will also be conducted following significant interactions in the mixed-effects models to compare the combined training group to the other three groups and to determine how early a group difference can be detected and whether the effect extends beyond the training period.

Changes in the serum levels of CRP, IL-1, IL-6, IL-8, TNF-α, S-100β, GFAP, BDNF, VEGF, and IGF-1, and plasma levels of amyloid beta Aβ42/Aβ40 will be calculated and used as the dependent variables in ANCOVA models with group as the independent variable and adjusting for stratification variables and baseline covariates that are found to be different among the groups in univariate comparisons. Post hoc comparisons will be used following a significant group effect to compare biomarker levels in the combined training group to the other three groups.

Missing data are expected due to patient death (mostly within 30 days of ICU discharge) and withdrawal from treatment. Patient death rates are expected to be equal across all four groups. The mixed-effects model approach is robust under the missing at random assumption, i.e. the probability of missing is unrelated to the missing observations. Baseline characteristics of subjects with missing outcomes due to death or dropout during follow-up will be compared to detect potential violation to the missing at random assumption. Intention to treat analysis will be used in all models. Further sensitivity analyses will be performed using various methods of imputation or a full parametric likelihood approach assuming various patterns of missing data \[[@CR42]\].

Sample size calculation was performed as follows. For the primary outcome to measure differences in cognitive effects, cognitive training has been found to have a moderate effect size of approximately 0.5 SD and the combined training was found to have a larger effect size of 0.9 SD when comparing to the control group in healthy elderly subjects \[[@CR43]--[@CR45]\]. Assuming effect sizes of 0.4 SD in the cognitive training only group and the exercise-only groups at 3 and 6 months post baseline compared to the attention control group and effect size of 0.8 SD in the combined training group at 3 and 6 months post baseline compared to the control group, a sample size of 60 patients in each group will yield 83% power at detecting a significant group by time interaction in a mixed-effects model adjusting for correlations of 0.2 for outcomes measured 3 months apart, and correlations of 0.1 for outcomes measured 6 months apart at α = 0.05. The power estimation was conducted using the GLMPower procedure in SAS. To further assume that 30% patients may miss some post-baseline assessments, we will need to enroll a total of 344 patients into the study (86 patients per group).

The proposed analyses for the outcomes for the mood questionnaires, physical performance battery, and quality of life scales will also have 83% power to detect effect sizes similar to those described for the primary outcome about cognitive effects. For the proposed analyses in changes in biomarkers, there will be 81.7% power to detect an overall treatment effect with effect sizes of 0.31 SD in the cognitive training only and the exercise only groups and 0.62 SD in the combined training groups at α = 0.05 using one-way ANOVA and the Power procedure in SAS.

Monitoring {#Sec8}
----------

The exercise program elements will include warm-up, flexibility exercise, moderate intensity exercise, and a gradual progression of exercise intensity and duration, and cool down. These elements are associated with lower risks of cardiovascular complications and muscular injury. The Interventionist will educate subjects about the signs and symptoms of angina, myocardial infarction, and muscle/tendon-related injuries and how to respond to them; a procedure recommended by the American College of Sports Medicine and the American Heart Association as effective means of reducing complications to exercise \[[@CR46], [@CR47]\]. The Data and Safety Monitoring Plan includes the identification and response to serious cardiac events and orthopedic injuries in the Protection of Human Subjects section. Interventionists will be alert to signs of anxiety and frustration displayed by subjects during cognitive training. Interventionists will monitor reactions closely and respond appropriately with encouragement and suggestions to reduce burden.

Discussion {#Sec9}
==========

Despite the high prevalence of post-ICU cognitive impairment and dementia, there are no effective and scalable recovery models to remediate these complications. IMPROVE represents a major step forward in the field of post-ICU cognitive impairment by proposing a novel home-based combined physical exercise and cognitive training program. The approach to deliver these trainings through the Internet increases the feasibility of participation and has the potential for widespread dissemination of this modality. The design of IMPROVE is based on a combination of previous knowledge about the effect of cognitive and physical training on cognitive outcomes and older adults, and the underlying pathophysiology of long-term cognitive impairment due to ICU delirium.

There are, however, limitations related to the sample. Previous studies suggest the majority of deaths and hospital readmission occur within the first 30 days of ICU discharge \[[@CR48], [@CR49]\]. More than 15% of ICU patients are hospitalized within 30 days of discharge \[[@CR49]\]. Likewise, the 30-day mortality rate for adult ICU patients is also higher than 15% \[[@CR48]\]. Exclusion criteria have been designed to increase the likelihood of selecting participants with at least a 6-month life expectancy. Assistive devices (glasses, headphones or pocket talker) will also be provided during interventions and assessments when indicated.

Despite these limitations, IMPROVE is innovative in several aspects. First, this is the first clinical trial in ICU survivors of delirium to examine the efficacy of interventions in isolation (physical exercise versus cognitive training versus attention control) or in combination (physical exercise plus cognitive training versus attention control). Second, this proposed intervention is based on plausible pathophysiologic pathways. The collection of biomarkers will help in establishing the mechanisms between cognitive activity, physical activity, and cognitive decline among ICU survivors of delirium. Third, this approach of using a combined physical exercise and cognitive training is an innovative behavioral intervention that has the potential for additive effects on enhancing cognitive recovery following critical illness. Finally, the proposed use of computers and broadband Internet to deliver the physical exercise and cognitive training to older ICU survivors in their homes using trained coaches via videoconference reduces task difficulty and is part of the growing movement championed by the Centers for Disease Control called Healthy Aging 2.0 which encourages health service delivery via the Internet \[[@CR50]\].

In summary, IMPROVE is the first randomized controlled trial to evaluate the efficacy of combined cognitive and physical training in improving the cognitive function among ICU survivors 50 or older who experienced delirium during their ICU stay. It will also provide valuable biomarker data to more deeply understand the pathophysiology of long-term cognitive impairment and dementia in survivors of ICU delirium, and potential therapeutic targets for future studies. Most importantly, this study will pave the way for a large effectiveness randomized controlled trial to test the combined intervention to delay time to a clinical diagnosis of Alzheimer disease and related dementias.

Trial status {#Sec10}
============

The study started recruiting October 1, 2017. The expected completion date is June 1, 2023.

Additional file
===============

 {#Sec11}

Additional file 1:SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*. (DOCX 41 kb)

ACTIVE

:   Advanced Cognitive Training for Independent and Vital Elderly

AD

:   Alzheimer disease

ANCOVA

:   Analysis of covariance

BDNF

:   Brain-derived neurotrophic factor

CAM-ICU

:   Confusion Assessment Method for the ICU

COPD

:   Chronic obstructive pulmonary disease

CRP

:   C-reactive protein

DAST-20

:   Drug Abuse Screening Test

GAD-7

:   Generalized Anxiety Disorder Scale

GFAP

:   Glial fibrillary acidic protein

ICU

:   Intensive care unit

IGF-1

:   Insulin growth factor-1

IL

:   Interleukin

IMPROVE

:   Improving Recovery and Outcomes Every Day after the ICU

MCS

:   Mental Component Summary

PCS

:   Physical Component Summary

PHQ-9

:   Patient Health Questionnaire-9

RBANS

:   Repeatable Assessment of Neuropsychological Status

RPE

:   Rating of perceived exertion

SD

:   Standard deviation

SF-36

:   36-Item Short Form Health Survey

SPPB

:   Short Physical Performance Battery

TNF

:   Tumor necrosis factor

VEGF

:   Vascular endothelial growth factor
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